Evaluation of BRAF mutations in patients with colorectal cancer in the east of Iran

Q4 Pharmacology, Toxicology and Pharmaceutics Current Pharmacogenomics and Personalized Medicine Pub Date : 2023-06-02 DOI:10.2174/1875692120666230602115139
M. Naseri, E. Serki, A. Mansouri, M. Malekaneh
{"title":"Evaluation of BRAF mutations in patients with colorectal cancer in the east of Iran","authors":"M. Naseri, E. Serki, A. Mansouri, M. Malekaneh","doi":"10.2174/1875692120666230602115139","DOIUrl":null,"url":null,"abstract":"\n\nSeveral genetic alterations in cell growth regulatory genes, such as BRAF, are associated with colorectal cancer. Due to the introduction of biological agents designed to treat cancer, diagnostic tests using nucleic acids extracted from formalin-fixed and paraffin-embedded tissues are becoming more common.\n\n\n\nThis study aimed to determine the incidence of BRAF mutations in colorectal cancer patients.\n\n\n\n50 paraffin-embedded cancer specimens were obtained from Imam Reza Hospital of Birjand in Iran. PCR was used to amplify and sequence the BRAF gene exon 15, which was extracted from paraffin-embedded tissue using an improved technique.\n\n\n\n2/43 (4%) of patients with colorectal cancer exhibited the BEAF V600E mutation. Most of the mutations occurred in patients over 50 years of age\n\n\n\nTo understand how genetics and environment interact to influence the low incidence of BRAF mutations in the east of Iran, further research is needed to determine what is driving this low incidence of BRAF mutations and what factors contribute to it.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"44 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692120666230602115139","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Several genetic alterations in cell growth regulatory genes, such as BRAF, are associated with colorectal cancer. Due to the introduction of biological agents designed to treat cancer, diagnostic tests using nucleic acids extracted from formalin-fixed and paraffin-embedded tissues are becoming more common. This study aimed to determine the incidence of BRAF mutations in colorectal cancer patients. 50 paraffin-embedded cancer specimens were obtained from Imam Reza Hospital of Birjand in Iran. PCR was used to amplify and sequence the BRAF gene exon 15, which was extracted from paraffin-embedded tissue using an improved technique. 2/43 (4%) of patients with colorectal cancer exhibited the BEAF V600E mutation. Most of the mutations occurred in patients over 50 years of age To understand how genetics and environment interact to influence the low incidence of BRAF mutations in the east of Iran, further research is needed to determine what is driving this low incidence of BRAF mutations and what factors contribute to it.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
伊朗东部结直肠癌患者BRAF突变的评估
细胞生长调节基因中的一些遗传改变,如BRAF,与结直肠癌有关。由于引入了用于治疗癌症的生物制剂,使用从福尔马林固定组织和石蜡包埋组织中提取的核酸进行诊断测试正变得越来越普遍。本研究旨在确定BRAF突变在结直肠癌患者中的发生率。50例石蜡包埋癌标本来自伊朗Birjand的Imam Reza医院。采用改进的技术从石蜡包埋组织中提取BRAF基因外显子15,采用PCR扩增并测序。2/43(4%)的结直肠癌患者出现BEAF V600E突变。大多数突变发生在50岁以上的患者中,为了了解遗传和环境如何相互作用来影响伊朗东部BRAF突变的低发病率,需要进一步的研究来确定是什么驱动了BRAF突变的低发病率,以及哪些因素导致了BRAF突变的低发病率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Pharmacogenomics and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
0.40
自引率
0.00%
发文量
11
期刊介绍: Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.
期刊最新文献
Association Study between rs10486567, rs13149290, rs1545985 and rs6983267 with Incidence of Prostate Adenocarcinoma Among Iranians Clinical Trial Participant's Perspectives on Genetic Research Data Re-uses for Future Research Exosome and Other Extracellular Vesicles in Gene Therapy and Personalized Care Generalized Analysis of Open Genetic Databases Reveals New Associations with Migraine Prediction Of Deleterious Non-Synonymous Single Nucleotide Polymorphism Of Cathelicidin
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1